- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05175664
Novel Diagnostic and Disease Stage Biomarkers in AD (TRACK-AD)
TRacking Alzheimer´s Disease: a Study of Disease trajeCtory and Development of Diagnostic and Disease Stage biomarKers in AD (TRACK-AD)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study consist of three sub-studies.
In study 1, participants diagnosed with mild cognitive impairment due to AD or mild to moderate AD will be followed for up to 24 months with repeated blood samples, pupillometry, actigraphy, cognitive tests and a control brain scan.
In study 2, patients under investigation of a neurodegenerative disease who have a planned lumbar puncture in the Memory clinic will be invited to this study. Participants will undergo pupillometry and blood samples two times approximately one and four weeks after the lumbar puncture.
In study 3, participants with a dementia diagnosis will undergo pupillometry and actigraphy at a single visit.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
-
Copenhagen, Denmark, 2100
- Danish Dementia Research Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Longitudinal study:
Inclusion criteria:
- MCI due to AD, or mild or moderate AD dementia according to the National Institute on Aging and Alzheimer's Association (NIA-AA) diagnostic criteria
- Caregiver willing to participate as an informant
- MMSE >19 at inclusion
- Brain FDG-PET/MRI or FDG/PET-CT
- Able to cooperate to the investigations and give informed consent
Exclusion criteria:
- Other neurological or psychiatric illness that may affect neurofilament light (NfL) levels (severe neuropathy, multiple sclerosis (MS), stroke within the last 3 months, Wernicke encephalopathy)
- Diagnosis of previous or current major psychiatric disorder (schizophrenia, bipolar disorder, psychosis) within last 2 years
- Excessive alcohol intake or substance abuse within the last 2 years
- Ophthalmological disorders that may affect pupillometry
- Participating in drug trials or other intervention trials
Short-term study:
Inclusion criteria:
- Patients under investigation of a neurodegenerative disease
- MMSE >19
- Scheduled lumbar puncture/lumbar puncture performed within the last week prior to inclusion
- Written consent form to the Danish Dementia Biobank
- Able to cooperate to the investigations
Exclusion criteria:
- Other neurological or psychiatric illness that may affect NfL levels (severe neuropathy, MS, stroke within the last 3 months, Wernicke encephalopathy)
- Excessive alcohol intake or substance abuse within the last 2 years
- Ophthalmological disorders that may affect pupillometry
- Participating in drug trials or other intervention trials
- Cross-sectional study:
Inclusion criteria - Patients:
- A diagnosis of a dementia disorder
- Caregiver willing to participate as an informant
- MMSE >15 at inclusion
- Able to cooperate to the investigations
- Able to give informed consent
Exclusion criteria - Patients:
- Diagnosis of previous or current major psychiatric disorder (schizophrenia, bipolar disorder, psychosis) within last 2 years
- Excessive alcohol intake or substance abuse within the last 2 years
- Other known brain disorder
- Ophthalmological disorders that may affect pupillometry
- Participating in drug trials or other intervention trials
Inclusion criteria - Healthy Controls:
- Able to cooperate to the investigations
- Normal cognition
- Age 50-90 year
Exclusion criteria - Healthy Controls:
- Diagnosis of previous or current major psychiatric disorder (schizophrenia, bipolar disorder, psychosis) within last 2 years
- Excessive alcohol intake or substance abuse within the last 2 years
- Other known brain disorder
- Ophthalmological disorders that may affect pupillometry
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
MCI
Patients suffering from mild cognitive impairment (MCI) due to Alzheimer's disease.
|
No intervention.
Investigations: cognitive tests, blood samples, pupillometry, actigraphy, and FDG-PET/MR brain scan.
|
AD
Patients diagnosed with mild to moderate Alzheimer's disease (AD)
|
No intervention.
Investigations: cognitive tests, blood samples, pupillometry, actigraphy, and FDG-PET/MR brain scan.
No intervention.
Investigations: cognitive tests, pupillometry and actigraphy.
|
NDD
Patients under investigation of a neurodegenerative disease (NDD)
|
No intervention.
Investigations: blood samples and pupillometry.
|
DLB
Patients diagnosed with Dementia with Lewy Bodies (DLB)
|
No intervention.
Investigations: cognitive tests, pupillometry and actigraphy.
|
VaD
Patients with vascular dementia (VaD)
|
No intervention.
Investigations: cognitive tests, pupillometry and actigraphy.
|
FTD
Frontotemporal dementia (FTD)
|
No intervention.
Investigations: cognitive tests, pupillometry and actigraphy.
|
NPH
Normal pressure hydrocephalus (NPH)
|
No intervention.
Investigations: cognitive tests, pupillometry and actigraphy.
|
Healthy Controls
Healthy Controls without brain disease
|
No intervention.
Investigations: cognitive tests, pupillometry and actigraphy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in CDR
Time Frame: Two years
|
Clinical Dementia Rating (CDR), a clinical tool for grading the relative severity of dementia with scores ranging from 0 (no impairment) to 3 (severe impairment).
|
Two years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in MMSE
Time Frame: Two years
|
Mini Mental Status Examination (MMSE), used to test global cognitive function
|
Two years
|
Changes in MR brain scan
Time Frame: 12 months
|
Magnetic Resonance Imaging (MR), used to asses changes in volumetric measurements
|
12 months
|
FDG-PET brain scan
Time Frame: 12 months
|
Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) of the brain, used to asses changes in brain metabolism
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Frederikke Kragh Clemmensen, MD, Danish Dementia Research Centre, Rigshospitalet, Copenhagen, Denmark
- Principal Investigator: Mathias Holsey Gramkow, MD, Danish Dementia Research Centre, Rigshospitalet, Copenhagen, Denmark
- Principal Investigator: Kristian Steen Frederiksen, MD, PhD, Danish Dementia Research Centre, Rigshospitalet, Copenhagen, Denmark
- Principal Investigator: Steen Gregers Hasselbalch, DMSc, Danish Dementia Research Centre, Rigshospitalet, Copenhagen, Denmark
- Principal Investigator: Anja Hviid Simonsen, MSc Pharm PhD, Danish Dementia Research Centre, Rigshospitalet, Copenhagen, Denmark
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Neurocognitive Disorders
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Tauopathies
- Cognition Disorders
- Intracranial Arterial Diseases
- Intracranial Arteriosclerosis
- Leukoencephalopathies
- Dementia
- Alzheimer Disease
- Cognitive Dysfunction
- Neurodegenerative Diseases
- Lewy Body Disease
- Dementia, Vascular
Other Study ID Numbers
- H-21040317
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on Long-term study
-
Hospices Civils de LyonActive, not recruitingCancer | SarcopeniaFrance
-
Ukraine Association of BiobankActive, not recruitingDiabete Type 2 | Mesenchymal Stem CellUkraine
-
Helsinki University Central HospitalCompleted
-
Mental Health Services in the Capital Region, DenmarkUniversity of Copenhagen; Copenhagen Trial Unit, Center for Clinical Intervention...Completed
-
Sun Yat-sen UniversityUnknownMultifocal Contact LensesChina
-
National Cancer Institute (NCI)Active, not recruitingCervical Carcinoma | Oral Cavity Carcinoma | Human Papillomavirus Infection | Anal Carcinoma | Human Papillomavirus-Related Cervical CarcinomaCosta Rica
-
Haukeland University HospitalOslo University Hospital; University Hospital of North Norway; Helse Stavanger... and other collaboratorsRecruitingNervous System Diseases | Neurodegenerative Diseases | Motor Neuron Disease | Amyotrophic Lateral Sclerosis | Spinal Cord Diseases | TDP-43 ProteinopathiesNorway
-
RenJi HospitalZhujiang Hospital; Clinical Research Institute, Shanghai Jiao Tong University...Not yet recruitingTraumatic Brain Injury | Subdural Effusion | Decompressive CraniectomyChina
-
University of BernCompletedDental Implants | PeriimplantitisSwitzerland
-
City of Hope Medical CenterActive, not recruiting